case_images: PMC2648641_01
case_images: MRI brain T1 with gadolinium
  after stopping bevacizumab with irinotecan.
case_images: JO2008-942618.001.jpg
case_images: PMC2648641_01_JO2008-942618.001.jpg
case_images: fig1
case_images: However, after seven cycles on this regimen a brain MRI showed increased mass effect and interval development of abnormal contrast enhancement in the medial hemispheric aspect of the right occipital and parietal lobe area, compatible with progression of disease (Figure 1).
case_images: Brain T1 with gadolinium
  prior to reinduction with bevacizumab with PLD.
case_images: JO2008-942618.002.jpg
case_images: PMC2648641_01_JO2008-942618.002.jpg
case_images: fig2
case_images: After 2 cycles on this regimen, his follow-up brain MRI showed  progression of disease (Figure 2).
case_images: Brain T1 with gadolinium
  after treatment with bevacizumab with PLD.
case_images: JO2008-942618.003.jpg
case_images: PMC2648641_01_JO2008-942618.003.jpg
case_images: fig3
case_images: His brain MRI  (T1 with gadolinium, FLAIR and T2 weighted images) after 4 treatments showed substantial  decrease in bulk of the large mass in the right posterior cerebral hemisphere with  associated decrease in edema (Figure 3).